Sapient Capital LLC Reduces Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sapient Capital LLC lessened its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 1.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,015 shares of the biotechnology company’s stock after selling 131 shares during the quarter. Sapient Capital LLC’s holdings in Sarepta Therapeutics were worth $1,297,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after acquiring an additional 243,180 shares during the last quarter. Capital International Investors boosted its holdings in shares of Sarepta Therapeutics by 160.0% during the 4th quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company’s stock valued at $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock worth $418,935,000 after buying an additional 319,444 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Sarepta Therapeutics by 5.6% in the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after buying an additional 217,810 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Sarepta Therapeutics in the fourth quarter worth approximately $80,697,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity

In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,815,030. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the business’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a total value of $1,848,750.00. Following the sale, the director now owns 22,840 shares in the company, valued at $2,815,030. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Bilal Arif sold 2,000 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $128.84, for a total transaction of $257,680.00. Following the completion of the sale, the insider now owns 26,836 shares in the company, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock worth $2,739,419 over the last quarter. Insiders own 7.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SRPT. Needham & Company LLC dropped their price objective on shares of Sarepta Therapeutics from $169.00 to $166.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. TheStreet raised shares of Sarepta Therapeutics from a “d” rating to a “c-” rating in a report on Monday, March 4th. Evercore ISI raised their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an “in-line” rating in a report on Tuesday, February 20th. UBS Group raised their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, Citigroup raised their price objective on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a “buy” rating in a report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $156.60.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded down $2.14 on Tuesday, hitting $126.66. 1,092,767 shares of the company traded hands, compared to its average volume of 998,905. The stock has a market capitalization of $11.97 billion, a P/E ratio of -20.70 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. Sarepta Therapeutics, Inc. has a 52 week low of $55.25 and a 52 week high of $159.89. The business has a 50-day simple moving average of $125.99 and a 200 day simple moving average of $110.36.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.50. The firm had revenue of $396.80 million for the quarter, compared to analysts’ expectations of $387.18 million. Sarepta Therapeutics had a negative net margin of 43.11% and a negative return on equity of 18.97%. The company’s revenue for the quarter was up 53.6% compared to the same quarter last year. During the same quarter last year, the business posted ($1.24) earnings per share. Research analysts expect that Sarepta Therapeutics, Inc. will post 2.13 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.